2001
DOI: 10.1038/sj.bjc.6692042
|View full text |Cite
|
Sign up to set email alerts
|

Soluble Fas ligand released by colon adenocarcinoma cells induces host lymphocyte apoptosis: an active mode of immune evasion in colon cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
7
0

Year Published

2004
2004
2018
2018

Publication Types

Select...
5
1

Relationship

1
5

Authors

Journals

citations
Cited by 14 publications
(7 citation statements)
references
References 29 publications
0
7
0
Order By: Relevance
“…For immunohistochemistry [ 36 ], the samples were incubated with an integrin β3 antibody at 4°C overnight. The sections were then treated with a secondary antibody, followed by further incubation with a streptavidin-horseradish peroxidase complex.…”
Section: Methodsmentioning
confidence: 99%
“…For immunohistochemistry [ 36 ], the samples were incubated with an integrin β3 antibody at 4°C overnight. The sections were then treated with a secondary antibody, followed by further incubation with a streptavidin-horseradish peroxidase complex.…”
Section: Methodsmentioning
confidence: 99%
“… 143 By targeting these two ligases, ceramide might enhance the efficacy of Fas ligand-based CRC therapy, particularly cytotoxic T-lymphocyte-based immunotherapy. 145 …”
Section: Ring-type E3 Ligases As Therapeutic Targetsmentioning
confidence: 99%
“…38 Similarly, sFasL shed from colon adenocarcinoma cells elicited apoptosis of Fas-expressing Jurkat cells. 39 However, other studies have shown that the cytotoxic activity of sFasL may be lacking or less potent. 40 , 41 sFasL may also act as a negative regulator that limits Fas-mediated cell death by competing with mFasL for Fas binding.…”
Section: Discussionmentioning
confidence: 99%